PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

被引：10

作者：

Minari, Roberta ^{[1
]}

Bonatti, Francesco ^{[1
]}

Mazzaschi, Giulia ^{[1
,2
]}

Dodi, Alessandra ^{[2
]}

Facchinetti, Francesco ^{[1
,3
]}

Gelsomino, Francesco ^{[4
]}

Cinquegrani, Gloria ^{[2
]}

Squadrilli, Anna ^{[1
]}

Bordi, Paola ^{[1
]}

Buti, Sebastiano ^{[1
]}

Bersanelli, Melissa ^{[1
]}

Leonetti, Alessandro ^{[1
]}

Cosenza, Agnese ^{[1
]}

Ferri, Leonarda ^{[1
]}

Rapacchi, Elena ^{[1
]}

Quaini, Federico ^{[2
]}

Ardizzoni, Andrea ^{[4
]}

Tiseo, Marcello ^{[1
,2
]}

机构：

[1] Univ Hosp Parma, Med Oncol Unit, Via Gramsci 14, I-43126 Parma, Italy

[2] Univ Parma, Dept Med & Surg, Parma, Italy

[3] Univ Paris Saclay, Inst Gustave Roussy, Biomarqueurs Predictifs & Nouvelles Strategies Th, INSERM, Villejuif, France

[4] AOU Policlin S Orsola Malpighi, Med Oncol, Bologna, Italy

来源：

TUMORI JOURNAL | 2022年 / 108卷 / 01期

关键词：

NSCLC; immunotherapy; PD-L1; SNPs; biomarker; CELL LUNG-CANCER; POLYMORPHISMS; ASSOCIATION; NIVOLUMAB; DOCETAXEL; EXPRESSION; PROGNOSIS; GENE;

D O I：

10.1177/03008916211014954

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype (p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.

引用

页码：47 / 55

页数：9

共 31 条

[1] Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients [J].

Bins, Sander ;

Basak, Edwin A. ;

el Bouazzaoui, Samira ;

Koolen, Stijn L. W. ;

Hoop, E. Oomen-de ;

van der Leest, Cor H. ;

van der Veldt, Astrid A. M. ;

Sleijfer, Stefan ;

Debets, Reno ;

van Schaik, Ron H. N. ;

Aerts, Joachim G. J. V. ;

Mathijssen, Ron H. J. .

BRITISH JOURNAL OF CANCER, 2018, 118 (10) :1296-1301

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[4] The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors [J].

Davis, Andrew A. ;

Patel, Vaibhav G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

[5] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[6] Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology [J].

Gridelli, Cesare ;

Ardizzoni, Andrea ;

Barberis, Massimo ;

Cappuzzo, Federico ;

Casaluce, Francesca ;

Danesi, Romano ;

Troncone, Giancarlo ;

De Marinis, Filippo .

TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (03) :373-386

[7]

Hashemi M., 2019, CANCERS, P11

[8] The biology and management of non-small cell lung cancer [J].

Herbst, Roy S. ;

Morgensztern, Daniel ;

Boshoff, Chris .

NATURE, 2018, 553 (7689) :446-454

[9] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer [J].

Herzberg, Benjamin ;

Campo, Meghan J. ;

Gainor, Justin F. .

ONCOLOGIST, 2017, 22 (01) :81-88

[10] Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer [J].

Lee, Shin Yup ;

Jung, Deuk Kju ;

Choi, Jin Eun ;

Jin, Cheng Cheng ;

Hong, Mi Jeong ;

Do, Sook Kyung ;

Kang, Hyo-Gyoung ;

Lee, Won Kee ;

Seok, Yangki ;

Lee, Eung Bae ;

Jeong, Ji Yun ;

Shin, Kyung Min ;

Yoo, Seung Soo ;

Lee, Jaehee ;

Cha, Seung Ick ;

Kim, Chang Ho ;

Park, Jae Yong .

GENE, 2017, 599 :28-35

← 1 2 3 4 →